While saliva obtained from HIV positive subjects is often PCR positive for HIV RNA sequences, it is extremely difficult to culture virus from oral samples. Coupled with the epidemiologic observations that HIV is rarely orally transmitted, it is now widely believed that saliva contains factors that inactivate the virus. We previously demonstrated that saliva from most individuals was able to specifically inhibit HIV-1 infection in vitro. Submandibular and parotid saliva samples from individuals demonstrating high levels of anti-HIV activity were used to identify and then purify two high molecular weight sialyated glycoproteins, salivary agglutinin (SAG) and mucin (MG2). Both of these purified glycoproteins inhibited HIV-1 infection in vitro at concentrations found in saliva. We subsequently demonstrated that the mechanism of inhibition involved binding of the salivary proteins to gp120, and subsequent shedding of gp120 from the virion. Prakobphol et al (2000), utilizing proteomic technology, demonstrated that SAG was identical to the lung scavenger receptor protein, gp-340, a member of the scavenger receptor cysteine rich (SRCR) family. We obtained a molecular clone for this gene, expressed the protein in mammalian cells and found that recombinant gp-340 was identical to SAG in terms of its structural and biologic activities. In the present proposal we will (1) Identify regions on gp120 that interact with gp-340; create stable transfected cells that express high levels of gp-340, and demonstrate that it is indeed identical to SAG in all of its biologic properties; (2) Identify discrete regions of gp-340 that mediate env binding and HIV inhibition; and (3) establish the mechanism(s) involved in the interaction of the bioactive portion of gp-340 in order to develop novel therapeutic agents with anti-HIV activity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
7R01DE014825-04
Application #
6934623
Study Section
Special Emphasis Panel (ZDE1-LK (53))
Program Officer
Mcinnes, Pamela M
Project Start
2002-09-15
Project End
2008-08-31
Budget Start
2005-09-01
Budget End
2008-08-31
Support Year
4
Fiscal Year
2005
Total Cost
$332,151
Indirect Cost
Name
New York University
Department
Other Basic Sciences
Type
Schools of Dentistry
DUNS #
041968306
City
New York
State
NY
Country
United States
Zip Code
10012
Malamud, D; Abrams, W R; Barber, C A et al. (2011) Antiviral activities in human saliva. Adv Dent Res 23:34-7
Malamud, Daniel; Wahl, Sharon M (2010) The mouth: a gateway or a trap for HIV? AIDS 24:5-16
Stoddard, Earl; Ni, Houping; Cannon, Georgetta et al. (2009) gp340 promotes transcytosis of human immunodeficiency virus type 1 in genital tract-derived cell lines and primary endocervical tissue. J Virol 83:8596-603
Stoddard, Earl; Cannon, Georgetta; Ni, Houping et al. (2007) gp340 expressed on human genital epithelia binds HIV-1 envelope protein and facilitates viral transmission. J Immunol 179:3126-32
Wu, Zhiwei; Lee, Sang; Abrams, William et al. (2006) The N-terminal SRCR-SID domain of gp-340 interacts with HIV type 1 gp120 sequences and inhibits viral infection. AIDS Res Hum Retroviruses 22:508-15
Cummins, James E; Christensen, Logan; Lennox, Jeffery L et al. (2006) Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses 22:788-95
Kariko, Katalin; Buckstein, Michael; Ni, Houping et al. (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:165-75
Wu, Zhiwei; Golub, Ellis; Abrams, William R et al. (2004) gp340 (SAG) binds to the V3 sequence of gp120 important for chemokine receptor interaction. AIDS Res Hum Retroviruses 20:600-7
Wu, Zhiwei; Chen, Zhiwei; Phillips, David M (2003) Human genital epithelial cells capture cell-free human immunodeficiency virus type 1 and transmit the virus to CD4+ Cells: implications for mechanisms of sexual transmission. J Infect Dis 188:1473-82
Wu, Zhiwei; Van Ryk, Donald; Davis, Cheryl et al. (2003) Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. AIDS Res Hum Retroviruses 19:201-9